Amneal Pharmaceuticals (AMRX) Reports Next Week: Wall Street Expects Earnings Growth

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Amneal Pharmaceuticals, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Amneal is expected to report quarterly earnings of $0.15 per share, reflecting a +7.1$707.4 million, up 14.7% from the previous year [3]. - The earnings report is scheduled for release on February 28, 2025, and could influence stock movement based on whether results exceed or fall short of expectations [2]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst assessments [4]. - A positive Earnings ESP of +2.27% suggests analysts have recently become more optimistic about Amneal's earnings prospects [10]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [8]. - Amneal currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [11]. Historical Performance - Amneal has consistently beaten consensus EPS estimates, achieving this in the last four quarters, including a +23.08% surprise in the most recent quarter [12][13]. Industry Context - BioCryst Pharmaceuticals, another player in the Zacks Medical - Drugs industry, is expected to report earnings of $0.06 per share, with a year-over-year change of +78.6$130.8 million, up 40% [17]. - BioCryst's Earnings ESP is -7.14%, making it challenging to predict a beat on the consensus EPS estimate, despite a Zacks Rank of 3 [18].